WO2018003531A1 - ピロロキノリンキノンモノナトリウム及びその製造方法、並びにそれを含む組成物 - Google Patents
ピロロキノリンキノンモノナトリウム及びその製造方法、並びにそれを含む組成物 Download PDFInfo
- Publication number
- WO2018003531A1 WO2018003531A1 PCT/JP2017/022206 JP2017022206W WO2018003531A1 WO 2018003531 A1 WO2018003531 A1 WO 2018003531A1 JP 2017022206 W JP2017022206 W JP 2017022206W WO 2018003531 A1 WO2018003531 A1 WO 2018003531A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- monosodium
- pqq
- crystal
- pyrroloquinoline quinone
- crystals
- Prior art date
Links
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 title claims abstract description 103
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 title claims description 26
- 239000000203 mixture Substances 0.000 title claims description 23
- 238000000034 method Methods 0.000 title claims description 14
- 239000013078 crystal Substances 0.000 claims description 196
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- DITJMKNNGYPPQD-UHFFFAOYSA-N 4,5-dioxo-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid;sodium Chemical compound [Na].C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 DITJMKNNGYPPQD-UHFFFAOYSA-N 0.000 claims description 28
- 239000002253 acid Substances 0.000 claims description 28
- UFVBOGYDCJNLPM-UHFFFAOYSA-L disodium;9-carboxy-4,5-dioxo-1h-pyrrolo[2,3-f]quinoline-2,7-dicarboxylate Chemical compound [Na+].[Na+].C12=C(C([O-])=O)C=C(C([O-])=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 UFVBOGYDCJNLPM-UHFFFAOYSA-L 0.000 claims description 20
- 239000007864 aqueous solution Substances 0.000 claims description 16
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 14
- JZCYGONDZRBSSA-UHFFFAOYSA-N 4,5-dioxo-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid;sodium Chemical compound [Na].[Na].[Na].C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 JZCYGONDZRBSSA-UHFFFAOYSA-N 0.000 claims description 10
- 230000005855 radiation Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- NKCXAUPYWYYCFE-UHFFFAOYSA-N [Na].N=1C(C(C=C2C=CC=CC12)=O)=O Chemical compound [Na].N=1C(C(C=C2C=CC=CC12)=O)=O NKCXAUPYWYYCFE-UHFFFAOYSA-N 0.000 claims description 2
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 description 281
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- 239000011734 sodium Substances 0.000 description 26
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 20
- 235000015424 sodium Nutrition 0.000 description 18
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 17
- 229910052708 sodium Inorganic materials 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 12
- 239000002537 cosmetic Substances 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000001735 carboxylic acids Chemical class 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000002441 X-ray diffraction Methods 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 235000013376 functional food Nutrition 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 159000000000 sodium salts Chemical class 0.000 description 6
- 238000001000 micrograph Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- -1 alkali metal salt Chemical class 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 229910001415 sodium ion Inorganic materials 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 244000294411 Mirabilis expansa Species 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000490 cosmetic additive Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001144 powder X-ray diffraction data Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZIUYHTQZEPDUCZ-UHFFFAOYSA-N 7h-pyrrolo[2,3-h]quinoline Chemical compound C1=CN=C2C(C=CN3)=C3C=CC2=C1 ZIUYHTQZEPDUCZ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PSJQCAMBOYBQEU-UHFFFAOYSA-N Glyoxalase I Natural products CC=CC(=O)OCC1=CC(O)C(O)C(O)C1=O PSJQCAMBOYBQEU-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000014017 Lactoylglutathione lyase Human genes 0.000 description 1
- 108010050765 Lactoylglutathione lyase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001437 anti-cataract Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000008519 pasta sauces Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/30—Further treatment of dried tea extract; Preparations produced thereby, e.g. instant tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention relates to pyrroloquinoline quinone monosodium, a method for producing the same, and a composition containing the same.
- PQQ Pyrroloquinoline quinone
- Many physiological activities such as an action, an anti-cataract action, a liver disease preventive and therapeutic action, a wound healing action, an anti-allergic action, a reverse transcriptase inhibitory action, a glyoxalase I inhibitory action and an anticancer action have been clarified. Therefore, PQQ is attracting attention as a useful substance in the pharmaceutical, food, and cosmetic fields.
- PQQ is expected to be applied as a therapeutic agent for heart, skin, nerves and the like.
- PQQ is expected to be applied as a substance having a beautifying effect.
- pyrroloquinoline quinone Since pyrroloquinoline quinone is produced by culturing and a production step is performed in an aqueous solution, it is usually obtained as an alkali metal salt.
- pyrroloquinoline quinone Although pyrroloquinoline quinone is known to be water-soluble, PQQ having a free structure shows low water solubility, and in fact, water solubility is improved by using an alkali metal salt of PQQ.
- the sodium salt of PQQ is easy to use because it is not toxic.
- the disodium salt of PQQ is recognized and used as a food.
- the crystal of the disodium salt of PQQ is known to be a hydrous crystal (see, for example, Patent Document 1, Non-Patent Documents 1 and 2).
- the pyrroloquinoline quinone monosodium salt represented by the following structural formula is suitable for use for different purposes because of its greatly different solubility compared to the disodium salt. For example, it is suitable when it is desired to slowly dissolve in water.
- a method for synthesizing a monosodium salt having a structure in which hydrogen and sodium at one site of a carboxylic acid of pyrroloquinoline quinone are replaced a method in which PQQ is dissolved in tetrahydrofuran and reacted with sodium hydroxide in an aqueous solution has been proposed (for example, , See Patent Document 2).
- tetrahydrofuran used in the method described in Patent Document 2 is flammable and is not a solvent that can be used for food.
- cultivated on neutral conditions is a structure which has a counter ion. Therefore, it is necessary to neutralize it by converting it to free form under acidic conditions.
- the obtained substance has a fiber state structure, is bulky, and lacks fluidity. Therefore, there exists a fault that the content in the same volume falls.
- fibrous crystals have poor fluidity in the solid state and are difficult to handle.
- pyrroloquinoline quinone sodium salt changes stability, handling, and color due to different binding sites and crystal structures of sodium.
- handling when it becomes a fibrous solid, it tends to be a film when filtered, and it is difficult to use because it has poor fluidity when handled as a powder.
- an operation of pulverizing the film-solidified state is required. Since such an operation is different from the known methods for producing crystals, it is relatively difficult to obtain stable crystals, and a stable crystal and a method for producing the same are desired. In order to obtain stable crystals, it is particularly important to increase the bulk density. Thereby, the fluidity can also be improved.
- a compound having a PQQ structure When a compound having a PQQ structure is applied to foods and cosmetics, a compound having a PQQ structure is required to be water-soluble, hardly change in color, and have high crystallinity. There is also a need for a method that can be manufactured safely and quickly.
- this invention is providing the pyrroloquinoline quinone monosodium which has a novel structure and the manufacturing method of pyrroloquinoline quinone monosodium which does not use a harmful organic solvent and does not contain a fibrous crystal and has a high bulk density. . It is another object of the present invention to provide a method for rapidly producing a pyrroloquinoline quinone monosodium crystal and a pyrroloquinoline quinone monosodium crystal having a novel structure.
- PQQ monosodium crystals having a novel structure can be obtained by preparing PQQ disodium or PQQ trisodium under specific conditions.
- the inventor has also found that the PQQ monosodium crystal is not easily discolored.
- the present invention is based on such knowledge.
- Dipyrroloquinoline quinone monosodium having a structure represented by the following formula (2).
- [7] The production method according to [5] or [6], wherein the step is performed in the presence of an aqueous solution having an ethanol concentration of 10 to 90% by mass.
- [8] The production method according to any one of [5] to [7], wherein a mixed crystal of pyrroloquinoline quinone disodium and pyrroloquinoline quinone monosodium is obtained in the step.
- [9] A composition comprising both pyrroloquinoline quinone monosodium according to [1] or [2] or dipyrroquinoline quinone monosodium according to [3] or [4] and pyrroloquinoline quinone disodium.
- the PQQ monosodium crystal of the present invention not only has high purity, but also has improved solubility, dispersibility in solution and permeability to skin, and is useful as a component of cosmetics, pharmaceuticals or functional foods.
- FIG. 2 is a photomicrograph of PQQ monosodium crystal 1 of Example 1.
- 2 is a powder X-ray diffraction pattern of the PQQ monosodium crystal 1 of Example 1.
- FIG. 3 is a powder X-ray diffraction pattern converted from PQQ monosodium crystal 1 single crystal data in Example 2.
- FIG. 2 is a micrograph of PQQ monosodium crystal 1 having a high bulk density according to Example 6.
- FIG. 4 is a photomicrograph of PQQ monosodium crystal 2 of Example 7.
- 4 is a powder X-ray diffraction pattern of PQQ monosodium crystal 2 of Example 7.
- FIG. It is the structure which showed the PQQ monosodium crystal 2 of Example 7 with the ball and stick.
- 2 is a photomicrograph of PQQ monosodium of Comparative Example 2.
- the PQQ monosodium of the present embodiment has a structure represented by the following formula (1), for example. These bond analyzes require single crystal structure analysis. Conventionally, it is considered that a carboxylic acid from which an acidic hydrogen atom has been removed and sodium are combined in a carboxylic acid salt of PQQ. A similar tendency is observed with the crystals of pyrroloquinoline quinone reported so far. However, pyrroloquinoline quinone monosodium (hereinafter also referred to as “PQQ monosodium 1”) having a structure represented by the following formula (1) has an unexpected structure from the conventional view.
- the structure of PQQ monosodium in this embodiment is bonded to the quinoline structure, and sodium is bonded to the carboxylic acid in which hydrogen remains, the nitrogen atom in the quinoline structure, and the oxygen atom bonded to the quinoline structure.
- hydrogen of the carboxylic acid that is bonded to the quinoline structure and not bonded to sodium is dissociated.
- 1 and 2 show the crystal structure of the PQQ monosodium 1 of the present embodiment in a ball and stick manner.
- the actual crystal of PQQ monosodium 1 of the present embodiment has a unit composed of two structures represented by the following formula (1).
- the PQQ monosodium of this embodiment also has a structure represented by the following formula (2), for example.
- Dipyrroloquinoline quinone monosodium having a structure represented by the following formula (2) (hereinafter also referred to as “PQQ monosodium 2”, and simply referred to as “PQQ monosodium” when not distinguished from PQQ monosodium 1)
- PQQ monosodium 2 Dipyrroloquinoline quinone monosodium having a structure represented by the following formula (2)
- PQQ monosodium 2 is bonded to the quinoline structure in one molecule of PQQ, and is bonded to the carboxylic acid in which hydrogen remains, the nitrogen atom in the quinoline structure, and the quinoline structure.
- Sodium is bonded to the carboxylic acid bonded to the quinoline structure in the oxygen atom and another molecule of PQQ, in which no hydrogen remains, and to the carboxylic acid bonded to the pyrrole structure.
- the crystal of PQQ monosodium in the present embodiment is preferably a water-containing crystal.
- a hydrous crystal for example, the crystal structure of a certain PQQ monosodium derived from the crystal structure analysis is a structure having two PQQ units and two sodium.
- the crystal of PQQ monosodium of this embodiment is different from the sodium salt reported so far, and is characterized in that it forms a bond with sodium as a non-ionized carboxylic acid COOH.
- a pyrroloquinoline quinone having such a bond is not known, and is a PQQ monosodium crystal having a novel bond.
- Crystals of PQQ monosodium 1 of the present embodiment are powder X-ray diffraction using Cu K ⁇ radiation, and are 7.9, 10.9, 11.2, 18.4. , 22.4, 25.7, 28.0, 28.8 ⁇ 0.4 ° PQQ monosodium crystal showing a peak of 2 ⁇ angle. This peak can be observed with a general powder X-ray diffractometer equipped with a monochromator.
- the crystal defined in the present embodiment is a crystal form having a reasonable identity with respect to the peak angle.
- the crystal water of the crystal 1 is, for example, 9.2% by mass. Actually, the amount of water varies depending on the influence of drying and humidity, and may be 15 to 18% by mass. This crystal form is a quadrangular prism. Since this crystal form is not fibrous, it is easy to handle as a powder.
- the crystal of PQQ monosodium 2 of the present embodiment (hereinafter also referred to as “crystal 2” and simply referred to as “crystal” when not distinguished from crystal 1) is obtained by powder X-ray diffraction using Cu K ⁇ radiation. , 9.9, 16.1, 16.8, 28.1 ⁇ 0.4 °, a PQQ monosodium crystal showing a 2 ⁇ angle peak.
- This crystal is a crystal obtained by further stabilizing the crystal form 1.
- the crystal 2 has a low water content.
- the water content of the crystal 2 is, for example, 4 to 7% by mass.
- Low water content pyrroloquinoline quinone monosodium is more hydrophobic and has the advantage of improved affinity with oil.
- the crystal 1 and the crystal 2 may be obtained in a mixed state.
- the method for producing pyrroloquinoline quinone monosodium includes a step of contacting pyrroloquinoline quinone disodium and / or pyrroloquinoline quinone trisodium with an acid.
- the acid is preferably an excess of acid.
- Production can be carried out rapidly by contacting with an excess of acid.
- the excess acid is preferably an acid amount of 2 to 200 times, more preferably 3 to 100 times, and still more preferably 5 to 5 times with respect to pyrroloquinoline quinone disodium and / or pyrroloquinoline quinone trisodium. 50 times.
- contact means that pyrroloquinoline quinone disodium and / or pyrroloquinoline quinone trisodium and acid are in contact with each other, and pyrroloquinoline quinone disodium and / or pyrroloquinoline. This includes adding an acid to quinone trisodium, and mixing pyrroloquinoline quinone disodium and / or pyrroloquinoline quinone trisodium with an acid.
- the crystals of PQQ monosodium obtained by the production method of the present embodiment are preferably used after being dried.
- the crystal can be dried by lyophilization, atmospheric drying, or vacuum drying.
- the drying temperature varies depending on the method, but can be, for example, ⁇ 80 to 250 ° C., preferably ⁇ 60 to 250 ° C.
- the lower limit of the drying temperature is a starting temperature at the time of freeze-drying, and the upper limit is a temperature at which no crystal decomposition occurs.
- the drying temperature can be ⁇ 80 to 0 ° C., preferably ⁇ 60 to 0 ° C. for freeze drying, 40 to 250 ° C. for atmospheric drying, and 0 for vacuum drying. It can be up to 250 ° C.
- the production method of this embodiment is characterized in that sodium ions are removed from pyrroloquinoline quinone disodium or pyrroloquinoline quinone trisodium.
- sodium ions are removed as the sodium salt of the acid. It is possible to crystallize at a high speed by using an excess acid, but at this time, it is preferable to allow sodium ions to coexist.
- sodium chloride in the case of hydrochloric acid and sodium sulfate in the sulfuric acid.
- the pyrroloquinoline quinone monosodium has low solubility, and the sodium salt to be removed is separated because of its high solubility.
- the PQQ monosodium crystal 1 of the present embodiment is produced, for example, by suspending or dissolving PQQ disodium or PQQ trisodium in water or ethanol water and adding an acid. Crystal 1 is produced by reacting PQQ disodium or PQQ trisodium with an acid in water or ethanol water.
- the PQQ monosodium of this embodiment is prepared by adding PQQ trisodium to an aqueous solution having an ethanol concentration of 0 to 90% by mass and then adding an acid to adjust the pH of the aqueous solution to 0 to By adjusting to the range of 2, it can be crystallized.
- the PQQ monosodium of this embodiment is prepared by adding PQQ disodium to an aqueous solution having an ethanol concentration of 0 to 90% by mass, and then adding an acid to adjust the pH of the aqueous solution to 0 to By adjusting to the range of 2, it can be crystallized. More specifically, when PQQ disodium is used as a raw material and an aqueous solution having an ethanol concentration of 20 to 80% by mass is used, the reaction time must be shorter than 12 hours. In this case, if the reaction is performed for a longer time (12 hours or longer), the crystal 2 is mixed.
- PQQ monosodium can be produced with an equivalent amount of acid in the case of PQQ disodium, and twice the amount of PQQ trisodium raw material. To quickly form crystals, an excess of acid may be added. At this time, the PQQ monosodium crystal 1 can be stably taken out by allowing a sodium salt, particularly sodium chloride to coexist.
- the crystal 1 of PQQ monosodium of this embodiment is in a metastable state immediately before forming a free body. For this reason, if the reaction is performed for a long time under this condition, crystals containing no sodium may be precipitated. Therefore, it is preferable to select appropriate conditions for crystal production by controlling time and temperature.
- the acid that can be used in the present embodiment is preferably a strong acid such as hydrochloric acid, sulfuric acid, or nitric acid, but a weak acid can similarly cause a reaction.
- Weak acids that can be used are, for example, acetic acid, lactic acid, formic acid, citric acid, phosphoric acid.
- the acid to be used is not limited, and may be performed under the condition that a target crystal is obtained.
- the step of adding an excess acid in the presence of salt it is preferable to perform the step of adding an excess acid in the presence of salt.
- the amount of sodium chloride is preferably 2 to 250 times, more preferably 5 to 100 times the mass of pyrroloquinoline quinone disodium and / or pyrroloquinoline quinone trisodium.
- the PQQ monosodium crystal 1 of the present embodiment can be obtained, for example, by reacting for 0.1 to 140 hours after setting the pH of the aqueous solution to a predetermined value. More preferably, the reaction time can be 0.5 to 96 hours.
- the reaction temperature can be 0 to 90 ° C, more preferably 3 to 60 ° C.
- the crystallization conditions can be freely selected in consideration of the presence or absence of stirring and the strength of the strength of the resulting crystal.
- the PQQ monosodium crystal 2 of the present embodiment can be obtained by, for example, reacting with PQQ disodium as a raw material in ethanol water, or recrystallizing the crystal 1 once crystallized in ethanol water. Easier conditions can be obtained by crystallization in an aqueous solution having an ethanol concentration of 20 to 80% by mass. These crystals can be produced and then recrystallized.
- the PQQ monosodium crystal 2 of the present embodiment can be obtained, for example, by reacting for 12 to 140 hours. More preferably, the reaction time can be 12 to 90 hours.
- the reaction temperature can be 0 to 90 ° C, more preferably 40 to 60 ° C.
- the obtained crystals can be obtained by filtration, centrifugation, and decantation. Further, it can be provided by washing with alcohol or the like.
- the step of adding an acid in the presence of an aqueous solution having an ethanol concentration of 10 to 90% by mass is preferably 15 to 85% by mass, more preferably 20 to 80% by mass, and further preferably 30 to 70% by mass.
- the PQQ monosodium crystals 1 and 2 of this embodiment have a high bulk density and are easy to handle. Further, the PQQ monosodium crystals 1 and 2 of this embodiment are easy to prepare because they do not change like gelation when added to the solution. Further, the PQQ monosodium crystal 2 of this embodiment is a low moisture content crystal and has a high bulk density. The PQQ monosodium crystals 1 and 2 of this embodiment further have an advantage of high purity because they are crystals. Furthermore, the PQQ monosodium crystals of this embodiment can be mixed with disodium for control of solubility, dissolution rate, and color.
- the composition of this embodiment contains both pyrroloquinoline quinone monosodium and pyrroloquinoline quinone disodium of this embodiment.
- the mixing ratio of pyrroloquinoline quinone monosodium and pyrroloquinoline quinone disodium is such that the crystal content of pyrroloquinoline quinone monosodium is preferably 5 to 95% by mass, more preferably 5 to 50% by mass. is there.
- the composition of this embodiment can be produced by mixing crystals, but it can also be produced by partially performing crystallization.
- a mixed crystal of pyrroloquinoline quinone disodium and pyrroloquinoline quinone monosodium can be obtained by adding excess acid to the above-described pyrroloquinoline quinone disodium and / or pyrroloquinoline quinone trisodium.
- the PQQ monosodium crystals 1 and 2 of this embodiment can be suitably used as foods, functional foods, nutrients, cosmetics, pharmaceuticals or quasi drugs for humans or animals.
- Functional food here means foods taken for the purpose of maintaining nutrition or supplementing nutrition, such as health foods, nutritional supplements, functional nutritional foods, nutritional health foods, and foods for specified health use.
- Specific forms of foods, functional foods, nutrients, cosmetics, pharmaceuticals or quasi drugs include capsules (eg gelatin capsules, soft capsules), tablets, chewable tablets, drinks, etc. It is not limited to these. Crystals 1 and 2 of PQQ monosodium in this embodiment are advantageous for being packed in capsules because of their high bulk density.
- a pharmaceutical composition containing the above-mentioned crystals of PQQ monosodium.
- the pharmaceutical composition of the present embodiment containing the above-mentioned crystals of PQQ monosodium can be a pharmaceutical composition for transdermal administration.
- the above-mentioned crystals of PQQ monosodium are excellent in dispersibility in fats and oils, they are suitable for formulation into oil-dispersed preparations.
- the pharmaceutical composition or cosmetic composition of the present embodiment containing the above-mentioned crystals of PQQ monosodium is preferably in the form of a dispersion preparation such as an emulsion or suspension, or a semi-solid such as an ointment or cream. It can be provided in the form of a formulation or in the form of a shaped formulation such as a soft capsule.
- sweeteners coloring agents, preservatives, thickening stabilizers, antioxidants, color formers, bleaching agents, antibacterial agents are used as additives.
- Antifungal agents, gum bases, bittering agents, enzymes, brighteners, acidulants, seasonings, emulsifiers, strengthening agents, manufacturing agents, fragrances, spice extracts and the like can be used.
- the above-mentioned PQQ monosodium crystals are generally used in normal foods such as miso, soy sauce, instant miso soup, ramen, fried noodles, curry, corn soup, merdofu, marvo eggplant, pasta sauce, pudding, cake, It can be added to bread and the like.
- the pharmaceutical composition of the present embodiment containing the above-mentioned PQQ monosodium crystal may contain the above-mentioned PQQ monosodium crystal and at least one pharmaceutical additive.
- the cosmetic composition of the present embodiment may contain the above-mentioned crystals of PQQ monosodium and at least one cosmetic additive.
- a pharmaceutical additive or cosmetic additive can be appropriately selected by those skilled in the art according to the formulation of the pharmaceutical composition or cosmetic composition.
- Powder X-ray diffraction uses RINT2500 manufactured by Rigaku Corporation, X-ray: Cu / tube voltage 40 kV / tube current 100 mA Scan speed: 4.000 ° / min Sampling width: 0.020 ° I went there.
- the water content (mass%) of the crystals was measured by the Karl Fischer method. Measuring method of Na amount
- the sodium electrode used HORIBA compact ion meter LAQUATwin. Dissolve 1 mg of sample in 1 mL of 0.5% aqueous choline hydroxide solution. This solution was measured with a 200 ⁇ L sodium electrode. The lower limit of detection was 1 ppm or less.
- Reference Example 1 Raw material PQQ trisodium and PQQ disodium PQQ disodium were manufactured by Mitsubishi Gas Chemical Co., Ltd. (trade name: BioPQQ). PQQ trisodium was obtained by salting out BioPQQ at pH 6-8.
- Example 1 Crystal form 1 pyrroloquinoline quinone monosodium (NaCl excess, hydrochloric acid excess) PQQ disodium (1.0 g) was mixed with NaCl (2 g), concentrated hydrochloric acid (7 mL), and water (1 L) at 37 degrees. At this time, NaCl was present in the solution 10 times or more and hydrochloric acid 30 times or more with respect to PQQ disodium. The mixture was stirred for 3 hours, then centrifuged, washed with 2-propanol, and dried to obtain crystals having a mass of 0.72 g. The obtained crystals were found to be PQQ monosodium from the amount of Na. A micrograph of the obtained PQQ monosodium crystal is shown in FIG.
- the result of the powder X-ray diffraction of the obtained crystal of PQQ monosodium is shown in FIG.
- the obtained crystals of PQQ monosodium were square and fluid particles. Even if this crystal
- the obtained crystals were 7.9, 10.9, 11.2, 18.4, 22.4, 25.7, 28.0, 28.8 ⁇ 0.4. It was found to be a PQQ monosodium crystal exhibiting a peak at 2 ° angle (FIG. 4). The water content of the obtained PQQ monosodium was 16.1% by mass.
- Example 2 Single crystal structure analysis Single crystal structure analysis was performed to determine the atomic arrangement of crystals. In powder X-ray diffraction (XRD), XYZ-axis peaks of crystals are mixed and measured, but in single-crystal structure analysis, these can be separated and measured, so that the position of atoms can be easily determined.
- XRD powder X-ray diffraction
- R-AXIS RAPID Imaging Plate Diffractometer manufactured by Rigaku Corporation was used for measurement. 50 mg of disodium salt was added to 15 mL of artificial gastric juice and stirred. The resulting solution was filtered through a 0.2 micrometer filter, and the filtrate was stored at 4 ° C. for 1 week. Single crystal structure analysis of the precipitated single crystal of dark red was performed.
- FIG. 6 shows a peak obtained by converting this crystal structure of the monosodium salt into powder X-ray diffraction data using Mercury, which is a structure analysis software. This peak was consistent with Example 1, and it was confirmed that all the crystal structures obtained by the present invention were the same.
- Example 3 Crystal 1 Preparation of high concentration of pyrroloquinoline quinone disodium 1 L of water was mixed with 2 g of NaCl and 7 mL of concentrated hydrochloric acid. PQQ disodium 0.6 g was mixed with 40 mL of this solution. The mixture was stirred at 37 ° C. for 3 hours, centrifuged, washed with 2-propanol and dried to obtain crystals having a mass of 0.56 g. The obtained crystals were found to be PQQ monosodium from the amount of Na. The powder X-ray analysis of the obtained PQQ monosodium crystal also had the same peak as in Example 1.
- Example 4 Crystal 1 High NaCl Concentration 0.50 g of PQQ disodium was mixed with 50 g of NaCl, 500 mL of water and 3.5 mL of concentrated hydrochloric acid, and reacted at 37 ° C. overnight. The obtained reaction solution was centrifuged, washed with 2-propanol, and dried to obtain crystals having a mass of 0.41 g. The obtained crystals were found to be PQQ monosodium from the amount of Na. The powder X-ray analysis of the obtained PQQ monosodium crystal also had the same peak as in Example 1.
- Example 5 Crystal 1 Pyrroquinoline quinone trisodium raw material
- the pyrroloquinoline quinone trisodium obtained in Reference Example 1 was used.
- PQQ trisodium (0.50 g) was mixed with NaCl (50 g), water (500 mL), and concentrated hydrochloric acid (3.5 mL), and reacted at 37 ° C. overnight.
- the obtained reaction solution was centrifuged, washed with 2-propanol, and dried to obtain crystals having a mass of 0.32 g.
- the obtained crystals were found to be PQQ monosodium from the amount of Na.
- the powder X-ray analysis of the obtained PQQ monosodium crystal also had the same peak as in Example 1.
- Example 6 Crystal 1 Sample with large bulk specific gravity 2 g of PQQ trisodium, 25 mL of ethanol, 20 mL of water, and 5 mL of 2N hydrochloric acid were stirred at room temperature for 1 hour and reacted at 50 ° C. for 5 days. The obtained reaction solution was centrifuged, washed with 2-propanol, and dried to obtain crystals having a mass of 1.46 g. The obtained crystals also had the same peak as in Example 1 in the powder X-ray analysis of the obtained PQQ monosodium crystals. Moreover, the water content of the obtained PQQ monosodium was 15.7 mass%. Moreover, the micrograph of the obtained PQQ monosodium is shown in FIG. The bulk density increased as the crystals became larger. The fluidity was also very good compared to small crystals.
- Example 7 Crystal 2 2 g of pyrroloquinoline quinone disodium was added to a mixed solution of 25 mL of ethanol and 22.5 mL of water. To this, 2.5 mL of 2N hydrochloric acid was added and stirred at room temperature for 1 hour. This suspension was heated to 50 ° C. to obtain a sample. After 5 days, the sample was filtered and dried under reduced pressure to obtain a crystal having a mass of 1.71 g. The obtained crystals were found to be PQQ monosodium from the amount of Na. Moreover, the micrograph of the obtained PQQ monosodium is shown in FIG. The result of the powder X-ray analysis of the obtained PQQ monosodium is shown in FIG.
- the water content of the obtained PQQ monosodium was 5.0% by mass. It was a crystal with a low water content.
- the single crystal structure analysis of the crystal 2 was performed in the same manner as in Example 2. As a result, it was a monosodium salt having the structure shown in FIG.
- Comparative Example 1 Reaction of PQQ disodium and hydrochloric acid alone (conditions not containing salt) PQQ disodium (1.0 g) was mixed at 37 degrees with 7 mL of concentrated hydrochloric acid and 1 L of water. At this time, it was present in the solution of hydrochloric acid 30 times or more with respect to PQQ disodium. The obtained solution was stirred for 3 hours, centrifuged, washed with 2-propanol, and dried to obtain 0.71 g of crystals. The obtained crystal did not contain Na amount. Under these conditions, the obtained crystal was found to be PQQ free. It has been found that if sodium ions, which are a feature of the production of the present invention, are not added excessively, sodium may be dropped from the crystals and monosodium cannot be produced.
- the obtained crystal was found to be a PQQ free body with no Na content and no sodium.
- the PQQ free body obtained by this method was used as a raw material.
- the PQQ free form was dissolved in tetrahydrofuran and mixed with an aqueous sodium hydroxide solution.
- a micrograph of the obtained crystal is shown in FIG. Unlike the Examples, the obtained monosodium salt contained a long and thin fibrous solid. Furthermore, the obtained monosodium salt was very small, and the filtration solid became a film.
- the water content of the obtained monosodium salt was 16.6% by mass.
- the structure of the monosodium salt described in Patent Document 2 was as follows.
- the bulk specific gravity of the crystal of Example is large, and the capsule can be made small if it has the same mass.
- the ability to use small capsules is easy to swallow and has the advantage of reducing the burden on the user.
- Suspension fluidity test crystals were mixed with water to a concentration of 100 g / L. After mixing at room temperature, the temperature was observed at 4 ° C.
- the crystal of the example has fluidity even in a dense state. This has the advantage that it can be provided as a concentrated solution in the process of solution preparation.
- the material of Comparative Example 2 has no fluidity and is difficult to use in a process prepared with a solution.
- Examples 8-14 Solubility and Color of Mixture The monosodium crystal 1 used in Example 1 and the monosodium crystal 2 prepared in Example 7 were used. Powders were mixed at the ratio shown in Table 3 and the color of the powder was recorded. 1 mL of water was added to a crystal mass of 10 mg at room temperature. The obtained aqueous solution was subjected to ultrasonic waves for 5 minutes, heated with 70 ° C. hot water for 10 minutes, and then cooled to room temperature for 30 minutes. The aqueous solution after cooling was centrifuged to remove the supernatant. This was diluted with a phosphate buffer, and the solubility was calculated from the absorbance at 330 nm. The results are shown in Table 3.
- Example 15 Preparation of a mixture of monosodium crystals and disodium 2 g of PQQ disodium was mixed with 25 g of ethanol and 23 g of water. 2N hydrochloric acid 2mL was added here. This was stirred at room temperature for 2 hours and left unstirred at 50 degrees for 18 hours. This was filtered, washed with ethanol, and dried under reduced pressure. A dark brown solid was obtained. The obtained solid had a sodium ratio of 1.5. As a result of observation with an optical microscope, the obtained solid was a mixture containing PQQ monosodium crystals 2.
- Example 16 Capsules Capsule # 0 made of hydroxypropylmethylcellulose sold by Great England Co., Ltd. was used. A capsule was filled with 20 mg of the crystal sample obtained in the above-mentioned Examples and Comparative Examples. Crystals 1 and 2 could be encapsulated as they were. The solid of Comparative Example 2 was too bulky to be put directly. I was able to stuff it by crushing in a mortar. The crystals of the examples were suitable for the use of hard capsules because they could be introduced into capsules without any operation of crushing solids.
- Example 17 Thermal stability test (70 ° C discoloration test) 1 mg of the crystals obtained in Examples 1 and 6 and Comparative Example 2 were placed in a 70 ° C. oven and the color change after 2 hours was observed. The results are shown in Table 4.
- the crystals 1 and 2 of the example were stable and did not change color even at 70 ° C.
- Example 18 Thermal stability test (change in solubility at 180 ° C. for 10 minutes) It was tested whether the solubility of crystals by heat treatment changed. 1 mg of the crystals obtained in Examples 1 and 6 and Comparative Example 2 were sandwiched between glass cover glasses and heated on a hot plate at 180 ° C. for 10 minutes. Thereafter, the crystals were mixed with 10 mL of water and stirred for 15 minutes. The situation was recorded at this time. The aqueous solution after stirring was filtered with a 0.5 ⁇ m filter, diluted to 1/10, and the absorbance at 330 nm was measured. From this measurement, the change in solubility of the crystals before and after the heat treatment was examined. Table 5 shows the solubility after heating with the solubility of crystals before heating as 100.
- Example 19 Reaction with Matcha 2 mg of Matcha was mixed with 1 mg of the crystals obtained in Examples 1 and 6 and Comparative Example 2. 100 ⁇ L of water was added as a model in which the mixed powder was wet. In Crystal 2, the tea leaves did not change color. However, the crystal 1 and the fiber (Comparative Example 2) turned orange. Crystal 2 was very stable and excellent in powder mixing.
- Example 20 Skin Permeability Test Porcine skin was washed with tap water and completely wiped off moisture. Each 5 mg of crystals was brought into contact with the pig's skin, and then wrapped and fixed to the skin. After 80 minutes at 37 ° C., the tape was peeled off, and the skin was washed with tap water to remove the test composition adhering to the skin surface. The test composition was taken in with a scanner and evaluated by measuring changes in skin brightness using image software (product name: Paint (Windows (registered trademark) XP attached software), manufactured by Microsoft Corporation). At this time, changes in skin brightness [[Untreated skin brightness-brightness after treatment] / [untreated skin brightness]] ⁇ 100 Calculated by
- the crystals of the examples had excellent skin penetration and were suitable for use in cosmetic applications.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
下記構造式で示されるピロロキノリンキノンモノナトリウム塩はジナトリウム塩に比べ、溶解性が大きく異なっていることから、異なる使用目的で使用するのに適している。例えば、水への溶解をゆっくりとしたい場合に適している。
PQQの構造を有する化合物を食品や化粧品に応用する上では、PQQの構造を有する化合物には水溶性で色が変化しにくく結晶性が高いものが求められる。また、安全で迅速に製造できる方法が求められている。
[1]
下記式(1)に示される構造を有するピロロキノリンキノンモノナトリウム。
結晶であり、Cu Kα放射線を用いた粉末X線回折で7.9、10.9、11.2、18.4、22.4、25.7、28.0、28.8±0.4°に2θ角度のピークを示す[1]に記載のピロロキノリンキノンモノナトリウム。
[3]
下記式(2)に示される構造を有するジピロロキノリンキノンモノナトリウム。
結晶であり、Cu Kα放射線を用いた粉末X線回折で9.9、16.1、16.8、28.1±0.4°に2θ角度のピークを示す[3]に記載のジピロロキノリンキノンモノナトリウム。
[5]
[1]に記載のピロロキノリンキノンモノナトリウムの製造方法であって、
ピロロキノリンキノンジナトリウム及び/又はピロロキノリンキノントリナトリウムと過剰の酸とを接触させる工程を含むピロロキノリンキノンモノナトリウムの製造方法。
[6]
前記工程を食塩存在下で行う[5]に記載の製造方法。
[7]
前記工程をエタノール濃度が10~90質量%の水溶液の存在下で行う[5]又は[6]に記載の製造方法。
[8]
前記工程でピロロキノリンキノンジナトリウムとピロロキノリンキノンモノナトリウムとの混合結晶を得る[5]~[7]のいずれかに記載の製造方法。
[9]
[1]又は[2]に記載のピロロキノリンキノンモノナトリウム或いは[3]又は[4]に記載のジピロロキノリンキノンモノナトリウムのいずれかとピロロキノリンキノンジナトリウムとを共に含む組成物。
図1及び図2は本実施形態のPQQモノナトリウム1の結晶構造をボールアンドスティックで示したものである。本実施形態のPQQモノナトリウム1の実際の結晶は下記式(1)に示される構造2つからなるユニットを有している。
ここで食塩の量は、ピロロキノリンキノンジナトリウム及び/又はピロロキノリンキノントリナトリウムの質量に対して、好ましくは2~250倍であり、より好ましくは5~100倍である。
さらに本実施形態のPQQモノナトリウムの結晶は、溶解度、溶解速度、色の制御のためにジナトリウムと混合することができる。
本実施形態の組成物は、本実施形態のピロロキノリンキノンモノナトリウムとピロロキノリンキノンジナトリウムとを共に含む。
本実施形態の組成物において、ピロロキノリンキノンモノナトリウムとピロロキノリンキノンジナトリウムとの混合比率はピロロキノリンキノンモノナトリウムの結晶含量が好ましくは5~95質量%、より好ましくは5~50質量%である。本実施形態の組成物は結晶をそれぞれ混合して製造することもできるが、結晶化を部分的に行うことで製造することも可能である。すなわち上述したピロロキノリンキノンジナトリウム及び/又はピロロキノリンキノントリナトリウムに過剰の酸を加える工程でピロロキノリンキノンジナトリウムとピロロキノリンキノンモノナトリウムとの混合結晶を得ることができる。
本実施形態では、上述のPQQモノナトリウムの結晶を含んでなる、医薬組成物、化粧組成物、機能性食品及び栄養剤が提供される。特に上述のPQQモノナトリウムの結晶は皮膚に対する浸透性に優れることから、上述のPQQモノナトリウムの結晶を含む本実施形態の医薬組成物は、経皮投与用の医薬組成物とすることができる。また、上述のPQQモノナトリウムの結晶は油脂中における分散性に優れることから、オイル分散系の製剤への処方に適している。従って、上述のPQQモノナトリウムの結晶を含む本実施形態の医薬組成物や化粧組成物は、好ましくは、乳剤や懸濁剤のような分散製剤の形態、軟膏剤やクリーム剤のような半固形製剤の形態あるいはソフトカプセルのような成形製剤の形態で提供されうる。
X線:Cu/管電圧40kV/管電流100mA
スキャンスピード:4.000°/min
サンプリング幅:0.020°
で行った。
Na量の測定方法
ナトリウム電極はHORIBA コンパクトイオンメーター LAQUAtwin を使用した。
サンプル1mgを0.5%コリン水酸化物水溶液1mLに溶解する。この溶液を200μLナトリウム電極で測定した。検出下限1ppm以下であった。
PQQジナトリウムは三菱ガス化学株式会社製(商品名:BioPQQ)を使用した。PQQトリナトリウムはBioPQQをpH6-8で塩析することで得た。
結晶形1:ピロロキノリンキノンモノナトリウム(NaCl 過剰、塩酸過剰)
PQQジナトリウム1.0gをNaCl 2g、濃塩酸7mL、水1Lに37度で混合した。この時、PQQジナトリウムに対し、NaClは10倍以上、塩酸30倍以上溶液に存在した。3時間攪拌して、その後、遠心分離、2‐プロパノール洗浄、乾燥して質量0.72gの結晶を得た。得られた結晶は、Na量からPQQモノナトリウムであることが判明した。得られたPQQモノナトリウムの結晶の顕微鏡写真を図3に示す。さらに得られたPQQモノナトリウムの結晶の粉末X線回折の結果を図4に示す。
得られたPQQモノナトリウムの結晶は四角形であり、流動性のある粒子であった。この結晶はろ過を行ってもフィルム状にならず、分散性のよいものであった。短時間の処理時間で結晶化を行えた。
得られたPQQモノナトリウムの水分量は16.1質量%であった。
結晶の原子配置を決定するために単結晶構造解析を行った。粉末X線回折(XRD)では結晶のXYZ軸のピークが混合して測定されるが単結晶構造解析ではこれらを分離して測定できるため、原子の位置決定が容易に行える。株式会社RIGAKU製R-AXIS RAPID Imaging Plate Diffractometerを使用して測定した。
人工胃液15mLに50mgのジナトリウム塩を加え、攪拌した。得られた溶液を0.2マイクロメートルのフィルターでろ過し、ろ液を4℃で1週間保存した。析出した濃赤色の結晶一粒の単結晶構造解析を行った。その結果、図5に示す構造のモノナトリウム塩であった。
この構造はピロロキノリンキノン2つとナトリウム2つとからなる構造を有し、結晶水を4つ含んでいた。一般に予想される構造とは異なりナトリウムの位置は式(1)で示される位置にあったが、このナトリウムと結合するカルボン酸の水素は解離せずに結合していた。
モノナトリウム塩のこの結晶構造を構造解析ソフトであるマーキュリーで粉末X線回折のデータに変換したピークを図6に示す。このピークは実施例1と一致しており、本発明で得られる結晶構造はすべて同一であることが確認できた。
水1Lに対しNaCl 2g、濃塩酸7mLで混合した。この溶液40mLにPQQジナトリウム0.6gを混合した。37℃3時間攪拌し、遠心分離、2-プロパノール洗浄、乾燥して質量0.56gの結晶を得た。得られた結晶は、Na量からPQQモノナトリウムであることが判明した。得られたPQQモノナトリウムの結晶の粉末X線解析も実施例1と同一のピークを有していた。
PQQジナトリウム 0.50gをNaCl 50g、水500mL、濃塩酸3.5mLと混合し、37℃一晩反応させた。得られた反応液を、遠心分離、2-プロパノール洗浄、乾燥して質量0.41gの結晶を得た。得られた結晶は、Na量からPQQモノナトリウムであることが判明した。得られたPQQモノナトリウムの結晶の粉末X線解析も実施例1と同一のピークを有していた。
参考例1で得られたピロロキノリンキノントリナトリウムを使用した。PQQトリナトリウム 0.50gをNaCl 50g、水500mL、濃塩酸3.5mLと混合し、37℃一晩反応させた。得られた反応液を、遠心分離、2-プロパノール洗浄、乾燥して質量0.32gの結晶を得た。得られた結晶は、Na量からPQQモノナトリウムであることが判明した。得られたPQQモノナトリウムの結晶の粉末X線解析も実施例1と同一のピークを有していた。
PQQトリナトリウム2g、エタノール25mL、水20mL、2N塩酸5mLを室温で1時間攪拌した後、50℃5日間反応させた。得られた反応液を、遠心分離、2-プロパノール洗浄、乾燥して質量1.46gの結晶を得た。得られた結晶は、得られたPQQモノナトリウムの結晶の粉末X線解析も実施例1と同一のピークを有していた。また、得られたPQQモノナトリウムの水分量は15.7質量%であった。
また、得られたPQQモノナトリウムの顕微鏡写真を図7に示す。
結晶が大きくなることでかさ密度が高くなった。流動性も小さな結晶と比較して非常によかった。
ピロロキノリンキノンジナトリウム2gをエタノール25mL、水22.5mLの混合液に加えた。ここに2N塩酸2.5mL加え、室温で1時間攪拌した。この懸濁液を50℃に加熱してサンプルを得た。5日後、サンプルをろ過したのち、減圧乾燥して質量1.71gの結晶を得た。得られた結晶は、Na量からPQQモノナトリウムであることが判明した。
また、得られたPQQモノナトリウムの顕微鏡写真を図8に示す。得られたPQQモノナトリウムの粉末X線解析の結果を図9に示す。
得られたPQQモノナトリウムの水分量は5.0質量%であった。水分量の少ない結晶であった。
実施例2と同様に結晶2の単結晶構造解析を行った。その結果、図10に示す構造のモノナトリウム塩であった。
PQQジナトリウム1.0gを濃塩酸7mL、水1Lに37度で混合した。この時、PQQジナトリウムに対し塩酸30倍以上溶液に存在した。得られた溶液を、3時間攪拌、遠心分離、2-プロパノール洗浄、乾燥して質量0.71gの結晶を得た。得られた結晶は、Na量が含まれていなかった。この条件では得られた結晶はPQQフリー体であることが判明した。本発明の製造の特徴であるナトリウムイオンを過剰に入れないと結晶中からナトリウムが脱落してモノナトリウムを作ることができない場合があることがわかった。
中国公開公報(CN101885725A)に記載される内容にもとづく実験
ピロロキノリンキノンジナトリウム塩2gを水198gに加えてジナトリウム塩水溶液を得た。得られた溶液はNaOHでpH9にあわせた。次に、この溶液に和光純薬製濃塩酸を水で50%希釈した液7.7gを攪拌しながら添加してpHを0.9にした。得られた溶液を、30分攪拌後、析出した固体をろ過し、水、イソプロパノールで洗った。これを減圧乾燥50℃で一晩行った。回収した赤色結晶の質量は1.6gであった。Na分析によると、得られた結晶は、Na含有量0でナトリウムが含まれず、PQQフリー体であることがわかった。この方法で得られたPQQフリー体を原料にした。PQQフリー体をテトラヒドロフランに溶かし、水酸化ナトリウム水溶液と混合した。
得られた結晶の顕微鏡写真を図11に示す。
得られたモノナトリウム塩は実施例と異なり長細い繊維状の固体を含むものであった。さらに得られたモノナトリウム塩は、非常に小さく、ろ過固体はフィルム状になった。得られたモノナトリウム塩の水分量16.6質量%であった。例えば特許文献2に記載されているモノナトリウム塩の構造は以下のとおりであった。
10mLメスフラスコを使用してかさ密度を測定した。
その結果を表1に示す。
結晶を100g/L濃度になるように水と混合した。室温で混合後4℃にして様子を観察した。
混合物の溶解性及び色
モノナトリウム結晶1として実施例1、モノナトリウム結晶2として実施例7で作ったものを使用した。表3に示す割合で粉末を混合して粉末の色を記録した。室温で結晶質量10mgに水1mL加えた。得られた水溶液を、超音波に5分かけ、70度のお湯で10分温めたら、室温の水30分冷やした。冷却後の水溶液を、遠心分離して、上澄み液を取り出した。これをリン酸バッファーで希釈して330nmの吸光度より溶解度を算出した。その結果を表3に示す。
PQQジナトリウム2gをエタノール25gと水23gと混合した。ここに2N塩酸 2mL加えた。これを室温で2時間攪拌し、50度18時間攪拌せずに置いた。これをろ過し、エタノールで洗い、減圧乾燥した。こげ茶色の固体を得た。得られた固体は、ナトリウムが1.5の割合になっていた。光学顕微鏡観察の結果、得られた固体は、PQQモノナトリウム結晶2が含まれた混合物であった。
グレートアングランド株式会社販売のヒドロキシプロピルメチルセルロース製カプセル♯0を使用した。カプセルに20mgの上記実施例及び比較例で得られた結晶のサンプルをつめた。
結晶1と結晶2とではそのまま、カプセルに入れることができた。比較例2の固体ではかさが高く直接入れられなかった。乳鉢ですりつぶすことでつめることができた。
実施例の結晶は固体をつぶす操作をいれずにカプセルに導入でき、ハードカプセルの使用に関して適した結晶であった。
実施例1及び6並びに比較例2で得られた結晶1mgを70℃オーブンに入れ、2時間後の色の変化を観察した。
その結果を表4に示す。
熱処理による結晶の溶解性が変化するか試験した。
実施例1及び6並びに比較例2で得られた結晶1mgをガラス製カバーガラスにはさんでホットプレートで180℃10分加熱した。その後、結晶を水10mLに混合し、15分間攪拌した。この時様子を記録した。攪拌後の水溶液を0.5μmのフィルターで濾過し、1/10に希釈して330nmの吸光度を測定した。この測定より加熱処理前後の結晶の溶解性の変化を調べた。加熱前の結晶の溶解度を100として加熱後の溶解度を表5に示す。
実施例の結晶1及び2は食品加工で使われる高温でも安定であった。従来のものでは沈殿物ができ、変質していた。
抹茶2mgと、実施例1及び6並びに比較例2で得られた結晶1mgを混合した。混合粉末がぬれたモデルとして100μLの水を加えた。結晶2では茶葉は変色しなかった。しかし、結晶1及び繊維状(比較例2)ではオレンジ色に変色した。結晶2は非常に安定で粉末混合に優れていた。
ブタの皮膚を水道水で洗浄し、水分を完全に拭き取った。このブタの皮膚に結晶を5mgずつ接触させ、その後、ラップして皮膚に固定した。37℃、80分間後に、テープを剥がし、皮膚を水道水で洗浄して皮膚表面に付着した試験用組成物を除去した。試験用組成物をスキャナで取り込んで、画像ソフト(製品名:ペイント(ウィンドウズ(登録商標)XP付属ソフト)、マイクロソフト社製)を用いて皮膚の明るさの変化を測定することにより評価した。この際、皮膚の明るさの変化は
[[未処理の皮膚の明るさ-処理後の明るさ]/ [未処理の皮膚の明るさ]]×100
により算出した。
Claims (9)
- 結晶であり、Cu Kα放射線を用いた粉末X線回折で7.9、10.9、11.2、18.4、22.4、25.7、28.0、28.8±0.4°に2θ角度のピークを示す請求項1に記載のピロロキノリンキノンモノナトリウム。
- 結晶であり、Cu Kα放射線を用いた粉末X線回折で9.9、16.1、16.8、28.1±0.4°に2θ角度のピークを示す請求項3に記載のジピロロキノリンキノンモノナトリウム。
- 請求項1又は2に記載のピロロキノリンキノンモノナトリウムの製造方法であって、
ピロロキノリンキノンジナトリウム及び/又はピロロキノリンキノントリナトリウムと酸とを接触させる工程を含むピロロキノリンキノンモノナトリウムの製造方法。 - 前記工程を食塩存在下で行う請求項5に記載の製造方法。
- 前記工程をエタノール濃度が10~90質量%の水溶液の存在下で行う請求項5又は6に記載の製造方法。
- 前記工程でピロロキノリンキノンジナトリウムとピロロキノリンキノンモノナトリウムとの混合結晶を得る請求項5~7のいずれか一項に記載の製造方法。
- 請求項1又は2に記載のピロロキノリンキノンモノナトリウム或いは請求項3又は4に記載のジピロロキノリンキノンモノナトリウムのいずれかとピロロキノリンキノンジナトリウムとを共に含む組成物。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17819891.7A EP3480197B1 (en) | 2016-06-29 | 2017-06-15 | Pyrroloquinone quinone monosodium, method for manufacturing same, and composition including same |
JP2018525047A JP7335070B2 (ja) | 2016-06-29 | 2017-06-15 | ピロロキノリンキノンモノナトリウム及びその製造方法、並びにそれを含む組成物 |
CN201780036948.4A CN109311873A (zh) | 2016-06-29 | 2017-06-15 | 吡咯并喹啉醌单钠及其制造方法、以及含有其的组合物 |
KR1020187037542A KR102479748B1 (ko) | 2016-06-29 | 2017-06-15 | 피로로퀴놀린퀴논모노나트륨 및 그 제조방법, 그리고 이것을 포함하는 조성물 |
US16/309,179 US11021476B2 (en) | 2016-06-29 | 2017-06-15 | Pyrroloquinoline quinone monosodium and method for producing the same, and composition comprising the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016128941 | 2016-06-29 | ||
JP2016-128941 | 2016-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018003531A1 true WO2018003531A1 (ja) | 2018-01-04 |
Family
ID=60786637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/022206 WO2018003531A1 (ja) | 2016-06-29 | 2017-06-15 | ピロロキノリンキノンモノナトリウム及びその製造方法、並びにそれを含む組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11021476B2 (ja) |
EP (1) | EP3480197B1 (ja) |
JP (2) | JP7335070B2 (ja) |
KR (1) | KR102479748B1 (ja) |
CN (1) | CN109311873A (ja) |
WO (1) | WO2018003531A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3845074A4 (en) * | 2018-08-30 | 2021-10-27 | Mitsubishi Gas Chemical Company, Inc. | PHOTODEGRADATION INHIBITOR, DRINK WITH IT AND PROCESS FOR INHIBITING PHOTODEGRADATION |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115246829A (zh) * | 2021-04-27 | 2022-10-28 | 浙江医药股份有限公司新昌制药厂 | 吡咯并喹啉醌单钠盐、其制备方法及组合物 |
CN115724840A (zh) * | 2021-08-26 | 2023-03-03 | 浙江医药股份有限公司新昌制药厂 | 涉及一种吡咯并喹啉醌三钠盐结晶、其制备方法及包含其的组合物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62246575A (ja) * | 1986-04-17 | 1987-10-27 | Mitsubishi Gas Chem Co Inc | ピロロキノリンキノンの精製方法 |
CN101885725A (zh) | 2009-05-12 | 2010-11-17 | 江苏道琪生物科技有限公司 | 吡咯喹啉醌钠盐衍生物及其制备方法 |
WO2011007633A1 (ja) | 2009-07-16 | 2011-01-20 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンのナトリウム塩結晶 |
WO2011055796A1 (ja) * | 2009-11-06 | 2011-05-12 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンのフリー体 |
JP2016128941A (ja) | 2015-01-09 | 2016-07-14 | 日本電気株式会社 | 出力判定装置、出力判定方法、出力判定プログラム、及び、静的解析装置 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012019739A (ja) * | 2010-07-15 | 2012-02-02 | Mitsubishi Gas Chemical Co Inc | ストレス低減食品 |
ES2651238T3 (es) * | 2011-06-16 | 2018-01-25 | Mitsubishi Gas Chemical Company, Inc. | Cristal de sal disódica de pirroloquinolina quinona y procedimiento para su fabricación |
WO2013051414A1 (ja) | 2011-10-03 | 2013-04-11 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンアルコール付加物 |
JP2013112677A (ja) | 2011-12-01 | 2013-06-10 | Mitsubishi Gas Chemical Co Inc | ピロロキノリンキノンジナトリウム結晶 |
WO2014027669A1 (ja) | 2012-08-17 | 2014-02-20 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンテトラアルカリ塩及びその結晶、これらの製造方法、並びに、組成物 |
CN102942567B (zh) | 2012-11-09 | 2017-02-08 | 诸城市浩天药业有限公司 | 吡咯并喹啉醌的二钠盐结晶 |
WO2017050171A1 (zh) * | 2015-09-25 | 2017-03-30 | 浙江海正药业股份有限公司 | 吡咯并喹啉醌钠盐的晶型及其制备方法和用途 |
CN105315278B (zh) * | 2015-11-02 | 2018-01-16 | 诸城市浩天药业有限公司 | 吡咯喹啉醌a晶型及其制备方法 |
KR101885725B1 (ko) | 2016-03-29 | 2018-08-06 | 최이분 | 핫멜트 접착제를 이용한 날개사 제조장치 및 그 장치에 의해 제조된 날개사 |
-
2017
- 2017-06-15 EP EP17819891.7A patent/EP3480197B1/en active Active
- 2017-06-15 KR KR1020187037542A patent/KR102479748B1/ko active IP Right Grant
- 2017-06-15 US US16/309,179 patent/US11021476B2/en active Active
- 2017-06-15 CN CN201780036948.4A patent/CN109311873A/zh active Pending
- 2017-06-15 JP JP2018525047A patent/JP7335070B2/ja active Active
- 2017-06-15 WO PCT/JP2017/022206 patent/WO2018003531A1/ja unknown
-
2023
- 2023-04-18 JP JP2023068092A patent/JP2023099033A/ja not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62246575A (ja) * | 1986-04-17 | 1987-10-27 | Mitsubishi Gas Chem Co Inc | ピロロキノリンキノンの精製方法 |
CN101885725A (zh) | 2009-05-12 | 2010-11-17 | 江苏道琪生物科技有限公司 | 吡咯喹啉醌钠盐衍生物及其制备方法 |
WO2011007633A1 (ja) | 2009-07-16 | 2011-01-20 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンのナトリウム塩結晶 |
WO2011055796A1 (ja) * | 2009-11-06 | 2011-05-12 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンのフリー体 |
JP2016128941A (ja) | 2015-01-09 | 2016-07-14 | 日本電気株式会社 | 出力判定装置、出力判定方法、出力判定プログラム、及び、静的解析装置 |
Non-Patent Citations (2)
Title |
---|
IKEMOTO, K. ET AL.: "Crystal structure and characterization of pyrroloquinoline quinone disodium trihydrate", CHEMISTRY CENTRAL JOURNAL, vol. 6, 2012, pages 57, XP021137638, DOI: doi:10.1186/1752-153X-6-57 |
ISHIDA, T. ET AL.: "Molecular and crystal structure of PQQ (methoxatin), a novel coenzyme of quinoproteins: extensive stacking character and metal ion interaction", JOURNAL OF AMERICAN CHEMICAL SOCIETY, vol. 111, 1998, pages 6822 - 6828, XP008149475, DOI: doi:10.1021/ja00199a050 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3845074A4 (en) * | 2018-08-30 | 2021-10-27 | Mitsubishi Gas Chemical Company, Inc. | PHOTODEGRADATION INHIBITOR, DRINK WITH IT AND PROCESS FOR INHIBITING PHOTODEGRADATION |
TWI823998B (zh) * | 2018-08-30 | 2023-12-01 | 日商三菱瓦斯化學股份有限公司 | 光劣化抑制劑、含有其之飲料,及光劣化抑制方法 |
Also Published As
Publication number | Publication date |
---|---|
US20190330205A1 (en) | 2019-10-31 |
CN109311873A (zh) | 2019-02-05 |
EP3480197B1 (en) | 2024-04-03 |
EP3480197A1 (en) | 2019-05-08 |
JP7335070B2 (ja) | 2023-08-29 |
US11021476B2 (en) | 2021-06-01 |
JP2023099033A (ja) | 2023-07-11 |
JPWO2018003531A1 (ja) | 2019-04-18 |
KR20190022560A (ko) | 2019-03-06 |
EP3480197C0 (en) | 2024-04-03 |
KR102479748B1 (ko) | 2022-12-21 |
EP3480197A4 (en) | 2019-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012173217A1 (ja) | ピロロキノリンキノンジナトリウム塩の結晶およびその製造方法 | |
JP2023099033A (ja) | ピロロキノリンキノンモノナトリウム及びその製造方法、並びにそれを含む組成物 | |
JP5842819B2 (ja) | ピロロキノリンキノンのカルシウム塩 | |
WO2013100105A1 (ja) | メイラード反応阻害剤 | |
JP5979376B2 (ja) | 溶解性の高いピロロキノリンキノン塩及びその製造方法 | |
JP6160621B2 (ja) | ピロロキノリンキノンテトラアルカリ塩及びその結晶、これらの製造方法、並びに、組成物 | |
JP5803150B2 (ja) | ピロロキノリンキノンーシクロデキストリン包接体 | |
JP7362646B2 (ja) | 共結晶 | |
Liu et al. | The role of 3-OH in the self-assembly of pharmaceutical cocrystals of dihydroflavonol with 4, 4′-bipyridine | |
JP2013053115A (ja) | α環状ジペプチドの製造方法 | |
KR101882849B1 (ko) | 흑삼 추출물을 포함하는 금속 나노입자 제조용 조성물 및 이의 용도 | |
JP2011219388A (ja) | 吸湿性の低いピロロキノリンキノン固体 | |
JP2017031126A (ja) | ピロロキノリンキノン結晶の製造方法 | |
JP6825330B2 (ja) | オートファジー誘導剤 | |
JP2006508968A (ja) | ウルソル酸−大豆レシチン凍結乾燥ナノ粒子注射剤およびその製造方法 | |
US6271397B1 (en) | L-ascorbic acid-2-phosphoric acid potassium crystal and method for producing the same | |
KR101404990B1 (ko) | 코엔자임 q10 전분 복합체를 포함하는 기능성 음료 및 이의 제조방법 | |
Singh et al. | Evaluation of in-vitro anti-inflammatory activity of chebulinic acid from Terminalia chebula Linn. against the denaturation of protein | |
EP0962461B1 (en) | Crystalline potassium salt of L-ascorbic acid-2-phosphoric acid and method for producting the same | |
RU2429224C1 (ru) | Смешанный ангидрид дихлоруксусной и аминоуксусной кислот и способ его получения | |
JP2024057691A (ja) | ピロロキノリンキノン含有塩又はその溶媒和物、それらを含む組成物、及びその製造方法 | |
TW201742617A (zh) | 美白化粧料及其所含有的白蛋白類化合物之製造方法 | |
JP2003171302A (ja) | 抗炎症剤および組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018525047 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17819891 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20187037542 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017819891 Country of ref document: EP Effective date: 20190129 |